Investment Analysts’ Recent Ratings Updates for Alnylam Pharmaceuticals (ALNY)

Several analysts have recently updated their ratings and price targets for Alnylam Pharmaceuticals (NASDAQ: ALNY):

• 1/12/2026 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $472.00 price target on the stock.
• 1/12/2026 – Alnylam Pharmaceuticals had its price target lowered by analysts at Bank of America Corporation from $530.00 to $529.00. They now have a “buy” rating on the stock.
• 1/12/2026 – Alnylam Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $520.00 to $529.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Alnylam Pharmaceuticals had its price target lowered by analysts at Truist Financial Corporation from $535.00 to $530.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Alnylam Pharmaceuticals is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $500.00 price target on the stock.
• 12/15/2025 – Alnylam Pharmaceuticals had its price target lowered by analysts at Leerink Partners from $370.00 to $351.00. They now have a “market perform” rating on the stock.
• 12/11/2025 – Alnylam Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $495.00 to $508.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,510 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the completion of the sale, the executive vice president directly owned 29,728 shares of the company’s stock, valued at approximately $10,787,399.36. This represents a 4.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 56,955 shares of company stock worth $24,072,733. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.